Abstract 222: Serum Adiponectin Level and Incident Dementia in Patients with Vascular Risk Factors - Sub-analysis of OSACA2 Follow-up Study
Background and Purpose: Involvement of metabolic factors on dementia development has received much attention. However, several previous studies have yield contradictory results for the involvement of blood adipocytokine levels on cognitive decline and dementia. The aim of this study is to clarify whether serum adiponectin level is related to incident dementia in patients with vascular risk factors.
Methods: OSACA2 is a prospective cohort study for cardiovascular events and dementia in which patients with vascular risk factors undergo carotid ultrasound and blood sampling. Between 2001 and 2009, 1106 outpatients were enrolled. Among them, 466 patients who underwent brain MRI and had normal cognitive function were included in this study. High molecular weight adiponectin level was measured with frozen serum. Follow-up data for dementia occurrence were collected in June 2013.
Results: Among 466 subjects (mean: 67.8 years), serum adiponectin level was 4.33 + 2.95 μg/mL. Adiponectin level was lower in male than in female, and positively associated with body mass index. During the follow-up period of median 6.9 years, 47 patients had incident dementia (27 AD, 17 vascular dementia, 3 others). Age, baseline MMSE, eGFR and the presence of lacunar infarction were related to incident dementia. No difference in adiponectin level was found between patients with and without incident dementia (4.31+3.07 vs. 4.33+2.94 μg/mL). The survival analyses for dementia-free rate curves, determined with respect to median level of adiponectin, are shown in Figure. Risk of incident dementia in patients with high and low adiponectin levels were almost similar (Log-rank test: p = 0.868). Risk of AD and vascular dementia were also similar between two groups.
Conclusion: This study suggested that serum adiponectin level have little association with future dementia. The impact of metabolic factors on dementia would need to be evaluated not by adiponectin level but other biomarkers or parameters.
Author Disclosures: K. Kitagawa: None. K. Miwa: None. M. Sakaguchi: None. Y. Yagita: None. H. Mochizuki: None.
- © 2015 by American Heart Association, Inc.